Ocugen Inc

Затворен

1.48 -3.9

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.48

Максимум

1.55

Ключови измерители

By Trading Economics

Приходи

-1.5M

-19M

Продажби

1.7M

1.5M

EPS

-0.06

Марж на печалбата

-1,250.946

Служители

116

EBITDA

-987K

-17M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+479.04% upside

Дивиденти

By Acuity

Следващи печалби

31.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-61M

565M

Предишно отваряне

5.38

Предишно затваряне

1.48

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.06.2026 г., 23:56 ч. UTC

Ulta Beauty shares rose in after-market trading, though they remain below the 20-day moving average and near the lower end of their one-month range.

30.06.2026 г., 23:56 ч. UTC

Correlated Moves

After-market trading for the iShares Core U.S. Aggregate Bond ETF is roughly flat, reflecting routine performance amid slight gains in the US 2Y Treasury Bond.

30.06.2026 г., 23:52 ч. UTC

European equity indices rise as Germany's inflation falls below expectations, easing ECB tightening concerns, while Bitcoin declines amid market volatility.

30.06.2026 г., 23:52 ч. UTC

Global markets show mixed performance as European indices rise on tech optimism while U.S. stocks decline amid volatility, with the dollar strengthening against the yen and Bitcoin falling due to regulatory concerns.

30.06.2026 г., 23:52 ч. UTC

U.S. equity indices decline as tech stocks sell off, while European markets rise on positive economic data; dollar strengthens amid Fed rate hike expectations and Bitcoin drops 2.8%.

30.06.2026 г., 23:52 ч. UTC

Mixed Asia equity markets as Japan's optimism contrasts with U.S. profit-taking; Bitcoin declines amid shifting investor focus ahead of key U.S. employment data.

30.06.2026 г., 23:52 ч. UTC

Bank of Japan to release Q2 Tankan Index on June 30, with market expectations set at a stable 16.0 amid ongoing optimism in manufacturing sector.

30.06.2026 г., 23:52 ч. UTC

South Korea's Exports Expected to Surge Again Ahead of July 1 Release Amid Strong Semiconductor Demand and Positive Market Sentiment.

30.06.2026 г., 23:52 ч. UTC

South Korea's S&P Global Manufacturing PMI set for July 1, with positive trends expected amid regional growth signals and inflation concerns.

30.06.2026 г., 23:52 ч. UTC

ISM Manufacturing Employment Report Set for July 1: Market Eyes Mixed Economic Signals and Job Growth Ahead of Potential Fed Rate Hikes.

30.06.2026 г., 23:52 ч. UTC

Australia's Balance of Trade data set for July 2, 2026, anticipates a AUD 2.3 billion surplus amid mixed stock market sentiment and geopolitical concerns.

30.06.2026 г., 23:52 ч. UTC

ISM Manufacturing PMI for June 2026 set to release on July 1, forecasted at 54.0 amid cautious optimism and geopolitical tensions impacting market stability.

30.06.2026 г., 23:52 ч. UTC

Brazil's BCB Focus Market Readout on July 6, 2026, may signal interest rate adjustments amid mixed investor sentiment influenced by inflation and global market pressures.

30.06.2026 г., 23:52 ч. UTC

Brazil's Industrial Production Expected to Continue Growth Trend Ahead of July 2 Release Amid Record Oil Output from Petrobras

30.06.2026 г., 23:52 ч. UTC

Canada's Manufacturing PMI Release on July 2 Expected to Reflect Economic Resilience Amid Mixed Global Signals and Geopolitical Pressures.

30.06.2026 г., 23:52 ч. UTC

ECB Forum on Central Banking Set for July 2026 Amid Cautious Market Sentiment and Potential Changes to Interest Rates.

30.06.2026 г., 23:52 ч. UTC

Japan's Current Account Data Release on July 7, 2026, Expected to Reflect Economic Trends Amidst Cautious Investor Optimism.

30.06.2026 г., 23:51 ч. UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Europe ETF is lower in after-market hours, influenced by mixed returns from holdings like BCS and NOK, as well as broader market sentiment.

30.06.2026 г., 23:51 ч. UTC

ETF Constituents

Vanguard Small-Cap ETF declines after hours, impacted by significant losses in holdings like SSTK, BLDR, and TOL. Trading activity remains weak.

30.06.2026 г., 23:51 ч. UTC

ETF Constituents

VanEck Gold Miners ETF declines in after-market trading, following three consecutive lower daily closes. KGC, AEM, and NEM all recorded negative returns.

30.06.2026 г., 23:51 ч. UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

30.06.2026 г., 23:51 ч. UTC

Texas Instruments Inc. shares are trading higher in after-market hours, reflecting broader positive momentum in equity indices amid optimism around economic data and AI investments.

30.06.2026 г., 23:46 ч. UTC

NetEase Inc. shares are higher in after-market trading, reflecting unusual strength following three consecutive sessions of gains amid a positive trend in European equities.

30.06.2026 г., 23:46 ч. UTC

Lululemon Athletica Inc shares are lower in after-market hours, remaining near the lower end of their one-month range and below the 20-day moving average.

30.06.2026 г., 23:46 ч. UTC

ETF Constituents

iShares MSCI South Korea ETF declines after market close, influenced by mixed global equity performance. LG Display saw a positive return, while SK Telecom had minimal impact.

30.06.2026 г., 23:46 ч. UTC

ETF Constituents

iShares China Large-Cap ETF advances in after-market trading, influenced by JD's negative contribution. FXI remains near the lower end of its one-month range.

30.06.2026 г., 23:42 ч. UTC

Australia's Ai Group Industry Index plunges to -30.0, signaling severe industrial contraction amid mixed economic signals and persistent challenges.

30.06.2026 г., 23:42 ч. UTC

MBA 30-Year Mortgage Rate Release on July 1 Expected to Show Stability Amid High Borrowing Costs and Mixed Consumer Confidence in Housing Market

30.06.2026 г., 23:42 ч. UTC

Mexican Business Confidence Remains Low at 47.5 Points Ahead of Key EMOE Report Amid Regulatory Changes and Economic Uncertainties

30.06.2026 г., 23:42 ч. UTC

Australia's Building Permits Expected to Rise 0.01% Amid Cautious Economic Sentiment and Mixed Market Indicators

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

479.04% нагоре

12-месечна прогноза

Среден 9.67 USD  479.04%

Висок 12 USD

Нисък 7 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat